Payment overview · 2025
General Payments
$106.47
6 reported records · 5 companies
Healthcare provider profile · identity verified
Susannah E Johnson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW BERN, NC · NPI 1750606075
Verified facts
What the public records show
CMS Open Payments records show Susannah E Johnson, MD received $106.47 in general payments during 2025 across 6 reported records.
Novartis Pharmaceuticals Corporation accounted for 40.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Trelegy Ellipta.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $42.89 | 40.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.83 | 15.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.87 | 14.9% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $15.71 | 14.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.17 | 14.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $106.47 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $42.89 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 93 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
93 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
46 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 456 | 118 |
| Atorvastatin Calcium | Atorvastatin Calcium | 429 | 96 |
| Lisinopril | Lisinopril | 401 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 366 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 315 | 98 |
| Omeprazole | Omeprazole | 306 | 78 |
| Potassium Chloride | Potassium Chloride | 284 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 246 | 68 |
| Furosemide | Furosemide | 243 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 218 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 51 |
| Farxiga | Dapagliflozin Propanediol | 178 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 176 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 170 | 44 |
| Mounjaro | Tirzepatide | 165 | 36 |
| Famotidine | Famotidine | 154 | 44 |
| Gabapentin | Gabapentin | 140 | 29 |
| Metformin Hcl | Metformin Hcl | 124 | 33 |
| Sertraline Hcl | Sertraline Hcl | 123 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 117 | 27 |
| Eliquis | Apixaban | 114 | 26 |
| Trazodone Hcl | Trazodone Hcl | 114 | 28 |
| Ozempic | Semaglutide | 108 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 106 | 30 |
| Carvedilol | Carvedilol | 103 | 26 |
| Jardiance | Empagliflozin | 100 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 28 |
| Trulicity | Dulaglutide | 97 | 18 |
| Kerendia | Finerenone | 93 | 20 |
| Simvastatin | Simvastatin | 93 | 27 |
| Azithromycin | Azithromycin | 84 | 71 |
| Meloxicam | Meloxicam | 80 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 17 |
| Allopurinol | Allopurinol | 72 | 15 |
| Linzess | Linaclotide | 72 | 20 |
| Pregabalin | Pregabalin | 66 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 13 |
| Ezetimibe | Ezetimibe | 64 | 18 |
| Bupropion Xl | Bupropion Hcl | 61 | 20 |
| Nystatin | Nystatin | 60 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | suppressed |
| Januvia | Sitagliptin Phosphate | 58 | suppressed |
| Rybelsus | Semaglutide | 56 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | 11 |
| Donepezil Hcl | Donepezil Hcl | 54 | 12 |
| Sucralfate | Sucralfate | 53 | 19 |
| Cefdinir | Cefdinir | 50 | 41 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 12 |
| Montelukast Sodium | Montelukast Sodium | 48 | 14 |
| Prednisone | Prednisone | 48 | 28 |
| Tramadol Hcl | Tramadol Hcl | 48 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 14 |
| Entresto | Sacubitril/Valsartan | 46 | 15 |
| Nifedipine Er | Nifedipine | 46 | 16 |
| Alprazolam | Alprazolam | 45 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 20 |
| Fluconazole | Fluconazole | 43 | 35 |
| Metformin Hcl Er | Metformin Hcl | 43 | 11 |
| Synthroid | Levothyroxine Sodium | 43 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 24 |
| Telmisartan | Telmisartan | 42 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 26 |
| Colchicine | Colchicine | 37 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | 27 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Felodipine Er | Felodipine | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | suppressed |
| Valsartan | Valsartan | 31 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 24 |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | 11 |
| Belsomra | Suvorexant | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 11 |
| Febuxostat | Febuxostat | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | 14 |
| Indapamide | Indapamide | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Cholestyramine Light | Cholestyramine | 14 | suppressed |
| Dofetilide | Dofetilide | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | 12 |
| Metolazone | Metolazone | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $106.47 · 6 records | Novartis Pharmaceuticals Corporation | Kerendia, LEQVIO, Leqembi, TRELEGY ELLIPTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error